Company Profile

Sunovion Pharmaceuticals Inc (AKA:Sepracor Inc)
Profile last edited on: 2/17/2022            CAGE: 0RFU3

Bioactive membranes and other separation technologies for hemical processing and pharmaceutical fields
Year Founded
1984
1st Award Year
1986
Latest Award
1998
Program Status
Inactive (Acquired)
Popularity Index

WikiProfile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

84 Waterford Drive
Marlborough, MA 01752
   (508) 481-6700
   info@sepracor.com
   www.sepracor.com
Multiple Locations:   
Congressional District:   03
County:   Middlesex

Public Profile

In September 2009, Sepracor Inc was acquired by Japanese Pharmacuetical firm Dainippon Sumitomo Pharma. After the acquisition, Sepracor became a wholly owned subsidiary of Dainippon Sumitomo Pharma America Holdings, Inc., a wholly owned U.S. subsidiary of DSP, and continued operations based in Marlborough, Massachusetts and in Canada. In April 2010, DSP's original U.S. subsidiary, Dainippon Sumitomo Pharma America, Inc. (DSPA) was merged into Sepracor. Sunovion is the new company born of this union. Sunovion Pharmaceuticals Inc, is specialty pharmaceutical company developing improved versions of widely prescribed pharmaceutical compounds. The Improved Chemical Entities (ICE) development program identifies existing, widely prescribed drugs that might be replaced by improved single-isomer or active-metabolite forms of such drugs. Sepracor then seeks to develop ICEs that offer one or more benefits over the parent drugs, such as reduced side effects, improved therapeutic efficacy or effectiveness for new indications. The company has spun out several technology companies including publicly-traded BioSepra Inc. (NASDAQ: BSEP) and HemaSure, Inc. (NASDAQ: HMSR) and wholly-owned SepraChem Inc. and Versicor Inc.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
500+
Revenue Range
Over 50M
VC funded?
Yes
Public/Private
Publicly Traded
Stock Info
NASDAQ : SEPR
IP Holdings
250-500

Awards Distribution by Agency

Key People / Management

  Mark Iwicki -- President

  Timothy J Barberich

  Franco Castino

  Saburo Hamanaka -- Chairman and Chief Executive Officer

  Steven Jones

  Laurence Melnick

  James O Shea

  Stephen A Wald

  Victor H Woolley

SBIR firms in the news

There are no news available.